<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04010994</url>
  </required_header>
  <id_info>
    <org_study_id>StimulationMagd</org_study_id>
    <nct_id>NCT04010994</nct_id>
  </id_info>
  <brief_title>Treatment of Patients With Optic Nerve Damage Patients Using Electrostimulation</brief_title>
  <acronym>HomeStim</acronym>
  <official_title>Treatment of Patients With Optic Nerve Damage Patients Using Electrostimulation: a Home Stimulation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Magdeburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Magdeburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to investigate the possibilities of visual field enhancement
      with electrical stimulation (ES) as a home stimulation method, in a total of 50 patients with
      optical neuropathy, who have already been treated with ES in the past.

      Furthermore, factors responsible for response variability and treatment effectiveness are
      also explored: (i) the role of mental stress (or stress resilience), (ii) the status of
      biomarkers, such as the systemic stress hormone levels and blood supply to the eye and brain
      (specifically vascular dysregulation) and (iii) the influence of personality, anxiety,
      depression and lifestyle. The study serves to further validate this ES procedure for the
      treatment of visual impairment. Specifically, better efficacy, better compliance, lowest
      response variability are expected after long-term home use.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 5, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual field size</measure>
    <time_frame>3 months</time_frame>
    <description>Static perimetry and high resolution perimetry will be used to measure the visual field sizes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EEG connectivities in the visual system</measure>
    <time_frame>3 months</time_frame>
    <description>EEG recordings will be done using 128 channels, power spectra will be determined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of vascular regulation/dysregulation in the eye</measure>
    <time_frame>3 months</time_frame>
    <description>Dynamic vessel analysis will be used the measure blood flow in the eye</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Glaucoma</condition>
  <condition>Electrical Stimulation</condition>
  <condition>Home Treatment</condition>
  <arm_group>
    <arm_group_label>rtACS</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>repetitive transorbital ACS</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transorbital electrical stimulation</intervention_name>
    <description>Transorbital ACS using 8-12 Hz with 0,5-1,5 mA Intensity, during the first two weeks 1/day, after 2/week for 10 weeks, as a home treatment</description>
    <arm_group_label>rtACS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with glaucoma, disease duration at least 6 months

          -  stable visual field defect across baseline measurement (subjects with spontaneous
             fluctuations and recovery of vision excluded)

          -  presence of residual vision and detectable gradual transition between the intact and
             the absolutely blind part of the visual field according to evaluation of the clinician

          -  best corrected visual acuity at least 0.4 (20/50 Snellen) or better

        Exclusion Criteria:

          -  autoimmune diseases in the acute stage

          -  neurological and mental diseases

          -  diabetic retinopathy

          -  addictions

          -  hypertension (maximum 160/100 mmHg)

          -  retinitis pigmentosa-

          -  pathological nystagmus

          -  non-distant tumors or recurrent tumors

          -  photosensitivity

          -  pregnancy

          -  electric or electronic implants (e.g. heart pacemaker)

          -  metal implants in the eyes or head (with the exception of dental prosthesis or shunts)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute of Medical Psychology</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Gall C, Schmidt S, Schittkowski MP, Antal A, Ambrus GG, Paulus W, Dannhauer M, Michalik R, Mante A, Bola M, Lux A, Kropf S, Brandt SA, Sabel BA. Alternating Current Stimulation for Vision Restoration after Optic Nerve Damage: A Randomized Clinical Trial. PLoS One. 2016 Jun 29;11(6):e0156134. doi: 10.1371/journal.pone.0156134. eCollection 2016.</citation>
    <PMID>27355577</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 3, 2019</study_first_submitted>
  <study_first_submitted_qc>July 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2019</study_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Magdeburg</investigator_affiliation>
    <investigator_full_name>Bernhard A. Sabel</investigator_full_name>
    <investigator_title>Head of Institute, Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Optic Nerve Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be available without restriction</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After publication</ipd_time_frame>
    <ipd_access_criteria>Contact to the Principal investigator</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

